Webinar: Can AI replace humans in pharmacovigilance?

The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data...

”We need compatibility“

Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on ef...

The Swedish Academy of Sciences: “We have too many researchers”

Sweden does not need more researchers, but it does need better ones. According to the Royal Swedish Academy of Sciences, funding should be distributed to favour excellence.

Pfizer värvar FDA-topp – kritiseras hårt

Läkemedelsjätten Pfizers rekrytering av Patrizia Cavazzoni, tills helt nyligen toppchef vid FDA, som ny medicinsk chef får frän kritik från flera håll.

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Microscopy in Urinalysis: Observe Urine, Detect Abnormalities

Webinar on 18th March 2025, 10 AM - 11 AM CET.

100 years of Festo

The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...

Ytterligare läkemedelskandidat mot Alzheimers droppas

Ett litet schweiziskt biotechbolag avbryter en fas II-studien med sin läkemedelskandidat mot Alzheimers sjukdom. Beskedet kommer inte långt efter att Biogen och...

Medivir CEO on upcoming study: ”It's about working together with others”

Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...

Läkemedelsjättar i bitter strid om fetmauppstickare

Ett budkrig har brutit ut inom fetmabehandlingar, där Pfizer och Novo Nordisk slåss med näbbar, klor och miljardbelopp om att få köpa det nystartade läkemedelsbolaget Metsera.

Aurevia

Speed meets precision for high-density components

ZEISS METROTOM 800 320 kV.

Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?

Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.

The International Vaccine Institute’s office in Sweden is expanding

The International Vaccine Institute’s Stockholm office has been open for over a year. During the past year, training programmes and projects have been launched,...

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

The business coach: “We need to learn from our mistakes”

The past year has been challenging for many biotech companies, with several comapanies facing financial stress and bankruptcy. To understand how entrepreneurs c...

The Crucial Role of Core Imaging Facility Managers

User story from ZEISS and the University of York.

Pharma Outsourcing – Find the Right Partner (2026)

Quality assurance for research and development of medical devices

Overcome the hurdles of research, development, and QA lab environments within the regulated medical technology industry.

Reveal the Structures and Functions of Life

Super-resolution microscopes from ZEISS.

Kokainberoende råttor knarkade mindre med semaglutid

Läkemedel som innehåller semaglutid minskade suget hos kokainberoende råttor i en studie från Göteborgs universitet.

Svenska biotechbolag i samarbete om biologiska läkemedel

AAX Biotech och Toxotech har ingått ett strategiskt samarbete för att utveckla nya biologiska läkemedel.

New drug to simplify treatment of hemophilia

A new type of treatment for hemophilia, which only needs to be administered every two months, has been approved by the U.S. Food and Drug Administration (FDA).